Paper20125090
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].
Di Cosimo S and 1 other. Nat Rev Clin Oncol, 2010. Cited by 136 papers, by iCite.
Cite this record
ConductScience Library. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Papers, record 20125090. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20125090
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Biomarkers, Tumor | Major topic |
| Breast Neoplasms | Major topic |
| Enzyme Inhibitors | Major topic |
| Female | |
| Humans | |
| Neoplasm Staging | |
| Treatment Outcome |
Source PubMed
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19075286 | Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19075286 | PubMed |
| 2 | 12204533 | Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. | Cancer Cell | 2002 | https://conductscience.org/library/papers/12204533 | PubMed |
| 3 | 12223530 | The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. | Pharmacol Rev | 2002 | https://conductscience.org/library/papers/12223530 | PubMed |
| 4 | 16985247 | Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. | J Natl Cancer Inst | 2006 | https://conductscience.org/library/papers/16985247 | PubMed |
| 5 | 18829560 | NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Cancer Res | 2008 | https://conductscience.org/library/papers/18829560 | PubMed |
| 6 | 19617568 | Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19617568 | PubMed |
| 7 | 15681523 | Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15681523 | PubMed |
| 8 | 12359757 | Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. | Cancer Res | 2002 | https://conductscience.org/library/papers/12359757 | PubMed |
| 9 | 16000569 | A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/16000569 | PubMed |
| 10 | 20124182 | Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20124182 | PubMed |
| 11 | 15489913 | The interplay between Src family kinases and receptor tyrosine kinases. | Oncogene | 2004 | https://conductscience.org/library/papers/15489913 | PubMed |
| 12 | 19249681 | Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. | Cancer Cell | 2009 | https://conductscience.org/library/papers/19249681 | PubMed |
| 13 | 11208825 | Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. | J Clin Oncol | 2001 | https://conductscience.org/library/papers/11208825 | PubMed |
| 14 | 17064066 | N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. | J Med Chem | 2006 | https://conductscience.org/library/papers/17064066 | PubMed |
| 15 | 3798106 | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | Science | 1987 | https://conductscience.org/library/papers/3798106 | PubMed |
| 16 | 19289619 | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19289619 | PubMed |
| 17 | 9442882 | Cellular functions regulated by Src family kinases. | Annu Rev Cell Dev Biol | 1997 | https://conductscience.org/library/papers/9442882 | PubMed |
| 18 | 17397528 | FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. | Breast Cancer Res | 2007 | https://conductscience.org/library/papers/17397528 | PubMed |
| 19 | 17440164 | Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | J Natl Cancer Inst | 2007 | https://conductscience.org/library/papers/17440164 | PubMed |
| 20 | 17438091 | The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17438091 | PubMed |
Cited by88
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 136 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42438567 | Unveiling isoleucyl-tRNA synthetase 2 as a novel driver of breast cancer via β-catenin pathway activation. | J Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42438567 | PubMed |
| 42258564 | Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer. | IET Syst Biol | 2026 | https://conductscience.org/library/papers/42258564 | PubMed |
| 40574091 | Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40574091 | PubMed |
| 40555914 | KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway. | Breast Cancer | 2025 | https://conductscience.org/library/papers/40555914 | PubMed |
| 39775383 | Targeting necroptosis in MCF-7 breast cancer cells: In Silico insights into 8,12-dimethoxysanguinarine from Eomecon Chionantha through molecular docking, dynamics, DFT, and MEP studies. | PLoS One | 2025 | https://conductscience.org/library/papers/39775383 | PubMed |
| 39335478 | CAF-Associated Genes in Breast Cancer for Novel Therapeutic Strategies. | Biomedicines | 2024 | https://conductscience.org/library/papers/39335478 | PubMed |
| 38005235 | Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment. | Molecules | 2023 | https://conductscience.org/library/papers/38005235 | PubMed |
| 37025579 | Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An In Silico Approach. | Eur J Breast Health | 2023 | https://conductscience.org/library/papers/37025579 | PubMed |
| 36133695 | A conjugated 2D covalent organic framework as a drug delivery vehicle towards triple negative breast cancer malignancy. | Nanoscale Adv | 2022 | https://conductscience.org/library/papers/36133695 | PubMed |
| 34907082 | Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/34907082 | PubMed |
| 34069461 | Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. | Nutrients | 2021 | https://conductscience.org/library/papers/34069461 | PubMed |
| 33584787 | Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer. | Front Genet | 2020 | https://conductscience.org/library/papers/33584787 | PubMed |
| 32821156 | The Clinical Relevance and Function of Krüppel-Like Factor 16 in Breast Cancer. | Cancer Manag Res | 2020 | https://conductscience.org/library/papers/32821156 | PubMed |
| 32784973 | Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32784973 | PubMed |
| 32675392 | LncRNA NEAT1 accelerates breast cancer progression through regulating miR-410-3p/ CCND1 axis. | Cancer Biomark | 2020 | https://conductscience.org/library/papers/32675392 | PubMed |
| 32186756 | Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing. | Int J Mol Med | 2020 | https://conductscience.org/library/papers/32186756 | PubMed |
| 32062536 | Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. | Breast | 2020 | https://conductscience.org/library/papers/32062536 | PubMed |
| 32054043 | Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32054043 | PubMed |
| 31938048 | PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. | Theranostics | 2020 | https://conductscience.org/library/papers/31938048 | PubMed |
| 31801619 | ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer. | Clin Epigenetics | 2019 | https://conductscience.org/library/papers/31801619 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ERBB3 | 2065 | PubTator's text mining | https://conductscience.org/library/genes/2065 | NCBI Gene |
| HSP90AA1 | 3320 | PubTator's text mining | https://conductscience.org/library/genes/3320 | NCBI Gene |
| MET | 4233 | PubTator's text mining | https://conductscience.org/library/genes/4233 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20125090
GET https://conductscience.org/api/papers/v1/20125090/references?page=2